RT Journal Article
SR Electronic
T1 Proteomic Changes in the Human Cerebrovasculature in Alzheimer’s Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal Fluid
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.10.24301099
DO 10.1101/2024.01.10.24301099
A1 Wojtas, Aleksandra M.
A1 Dammer, Eric B.
A1 Guo, Qi
A1 Ping, Lingyan
A1 Shantaraman, Ananth
A1 Duong, Duc M.
A1 Yin, Luming
A1 Fox, Edward J.
A1 Seifar, Fatemeh
A1 Lee, Edward B.
A1 Johnson, Erik C. B.
A1 Lah, James J.
A1 Levey, Allan I.
A1 Levites, Yona
A1 Rangaraju, Srikant
A1 Golde, Todd E.
A1 Seyfried, Nicholas T.
YR 2024
UL http://medrxiv.org/content/early/2024/01/11/2024.01.10.24301099.abstract
AB Dysfunction of the neurovascular unit stands as a significant pathological hallmark of Alzheimer’s disease (AD) and age-related neurodegenerative diseases. Nevertheless, detecting vascular changes in the brain within bulk tissues has proven challenging, limiting our ability to characterize proteomic alterations from less abundant cell types. To address this challenge, we conducted quantitative proteomic analyses on both bulk brain tissues and cerebrovascular-enriched fractions from the same individuals, encompassing cognitively unimpaired control, progressive supranuclear palsy (PSP), and AD cases. Protein co-expression network analysis identified modules unique to the cerebrovascular fractions, specifically enriched with pericytes, endothelial cells, and smooth muscle cells. Many of these modules also exhibited significant correlations with amyloid plaques, cerebral amyloid angiopathy (CAA), and/or tau pathology in the brain. Notably, the protein products within AD genetic risk loci were found concentrated within modules unique to the vascular fractions, consistent with a role of cerebrovascular deficits in the etiology of AD. To prioritize peripheral AD biomarkers associated with vascular dysfunction, we assessed the overlap between differentially abundant proteins in AD cerebrospinal fluid (CSF) and plasma with a vascular-enriched network modules in the brain. This analysis highlighted matrisome proteins, SMOC1 and SMOC2, as being increased in CSF, plasma, and brain. Immunohistochemical analysis revealed SMOC1 deposition in both parenchymal plaques and CAA in the AD brain, whereas SMOC2 was predominantly localized to CAA. Collectively, these findings significantly enhance our understanding of the involvement of cerebrovascular abnormalities in AD, shedding light on potential biomarkers and molecular pathways associated with CAA and vascular dysfunction in neurodegenerative diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the following National Institutes of Health (NIH) funding mechanisms [U01AG061357 (A.I.L and N.T.S), RF1AG062181 (N.T.S.) and P30AG066511 (A.I.L)], the Foundations for the National Institute of Health AMP-AD 2.0 grant and a grant from the Alzheimer's Association (ABA-22-974673).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of the University of Pennsylvania gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.synapse.org/vascular https://www.synapse.org/vascular